Drugs / RO4987655
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00817518 | Jan 2009 → Dec 2014 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO4987655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00817518 ↗ |
| Known as | CH-4987655 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614766 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1614766 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1614766 ↗ “RO4987655, a MEK Inhibitor” NCT00817518 ↗ |
| Modality | Small molecule | — CHEMBL1614766 ↗ |
| Route | Oral | “Administered po daily for 28 days” NCT00817518 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1614766 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1614766 ↗ |